Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting
February 08 2022 - 8:00AM
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage
biopharmaceutical company advancing therapies for acute and chronic
gastrointestinal (GI) complications, announced today that data from
a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN
(PROFILE-CN) has been selected for a presentation in The Next Big
Thing session of the Society of American Gastrointestinal and
Endoscopic Surgeons (SAGES) 2022 Annual Meeting.
The data will be available via ePoster during the conference
from March 16 – 19, 2022 and will go live in conjunction with the
start of the conference on March 16. The title of the presentation
is Incidence and Severity of Post-Surgical Intraabdominal Adhesions
following Bowel Resection Surgery and Treatment with Enteral
Protease Inhibitor LB1148. Palisade Bio’s Chief Medical Officer,
Michael Dawson, M.D., will present the data in a public webinar
hosted by Stonegate Capital Partners the morning of March 16.
“It is an honor to be selected for participation in The Next Big
Thing session for SAGES, one of the world’s premier professional
organizations for gastrointestinal surgery,” said Dr. Dawson.
“Previously we announced data showing that patients treated with
LB1148 had a highly statistically significant 1.1-day improvement
in the return of bowel function following GI surgery in the
LBS-POI-201-CN study. We look forward to sharing this additional
data on the incidence and severity of adhesions from the pooled
analysis of patients treated with LB1148 to this professional
medical audience and the investor community.”
Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN) assessed
the efficacy of LB1148 to reduce the formation of adhesions in
subjects undergoing abdominal surgery. Study LBS-IST-POI-101 was a
Phase 1, single-center, open-label, study enrolling 11 subjects
undergoing GI surgery. The PROFILE-CN study was a 120-subject Phase
2, randomized, double-blind, placebo-controlled study conducted in
collaboration with co-development partner, Newsoara Biopharma to
evaluate LB1148 for return of GI function in subjects undergoing
elective bowel resection. In both trials, a subset of subjects went
on to have a second surgery (e.g., stoma take down). In these
subjects, adhesions were assessed and quantified at the time of
surgical closure during the initial surgery and at the time of
opening at the subsequent surgical procedure.
About LB1148
LB1148 is an oral formulation of a broad-spectrum serine
protease inhibitor designed to neutralize the activity of potent
digestive proteases released from the gut during surgery. Evidence
suggests that the release of digestive proteases contributes to the
temporary loss of normal gastrointestinal function and formation of
postoperative adhesions. By inhibiting the activity of these
digestive proteases, LB1148 has the potential to prevent damage to
GI tissues, accelerate the time to return of normal GI function,
and shorten the duration of costly post-surgery hospital stays.
About Palisade Bio
Palisade Bio is a clinical stage biopharmaceutical company
advancing therapies that help patients with acute and chronic
gastrointestinal complications stemming from post-operative
digestive enzyme damage. Palisade Bio’s innovative lead asset
LB1148, advancing towards Phase 3, is a protease inhibitor with the
potential to both reduce abdominal adhesions and help restore bowel
function following surgery. Positive data from Phase 2 trials of
LB1148 demonstrated safety and tolerability as well as a
statistically significant improvement in return to bowel function
and decrease in length of stay in ICU and hospital compared to
placebo. Palisade Bio believes that its investigational therapies
have the potential to address the myriad health conditions and
complications associated with chronic disruption of the
gastrointestinal epithelial barrier. For more information, please
go to www.palisadebio.com.
About Newsoara Biopharma
Newsoara is a biotech company based in Shanghai, China with
research laboratories in the Suzhou BioBAY focusing on novel drug
research and development to address unmet medical needs in patients
with various diseases.
Forward Looking Statements
This communication contains “forward-looking” statements,
including, without limitation, statements related to expectations
regarding Palisade’s plans for future presentations at investor
conferences. Any statements contained in this communication that
are not statements of historical fact may be deemed to be
forward-looking statements. These forward-looking statements are
based upon Palisade’s current expectations. Forward-looking
statements involve risks and uncertainties. Palisade’s actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
Company’s ability to advance its clinical programs and the
uncertain and time-consuming regulatory approval process.
Additional risks and uncertainties can be found in Palisade Bio’s
Quarterly Report on Form 10-Q for the quarter
ended September 30, 2021. Palisade expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Palisade’s expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based.
Palisade Bio Investor Relations Contact:Dawn
Hofmeisterir@palisadebio.com
Palisade Bio Media Relations Contact:CORE
IRJules Abrahamjulesa@coreir.com917-885-7378
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Oct 2023 to Oct 2024